Pulse Biosciences, Inc. PLSE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pulse Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pulse Biosciences, Inc.'s cash & equivalents?
- Pulse Biosciences, Inc. (PLSE) reported cash & equivalents of $68.32M in Q1 2026.
- How has Pulse Biosciences, Inc.'s cash & equivalents changed year-over-year?
- Pulse Biosciences, Inc.'s cash & equivalents decreased by 42.7% year-over-year, from $119.28M to $68.32M.
- What is the long-term trend for Pulse Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Pulse Biosciences, Inc.'s cash & equivalents has grown at a 45.3% compound annual growth rate (CAGR), from $12.46M to $80.74M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.